spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  valsartan 

 HSMN NewsFeed - 6 Sep 2018
Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to product/label mix-up
Biopharmaceuticals FDA Product Recall
 HSMN NewsFeed - 31 Aug 2018
FDA announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles
Biopharmaceuticals FDA Product Recall
 HSMN NewsFeed - 10 Jul 2018
Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 19 Jan 2017
Ezra Announces FDA Acceptance Of Filing Of New Drug Application For EZR-104 For The Treatment Of Hypertension And Heart Failure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 6 Jun 2016
Allergan Announces FDA Approval of BYVALSON(TM) (nebivolol and valsartan)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 29 Jan 2016
Viacoram(R) now approved in Canada as a new first line treatment in hypertension
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 19 May 2014
Genkyotex Announces New Senior Management and Board Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Nov 2010
NT-proBNP Guided Therapy Keeps Heart Failure Patients out of the Hospital Through a Reduction in Cardiovascular Events
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 Jun 2010
New Head-to-Head Phase 3 Study Evaluated Systolic Blood Pressure Reduction of Investigational Compound Azilsartan Medoxomil Compared to Valsartan
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 19 Oct 2009
FDA Approves New Use for Micardis(R) in Cardiovascular Risk Reduction and Twynsta(R) as New Combination Treatment for High Blood Pressure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 28 Jan 2009
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge in France
Biopharmaceuticals
 HSMN NewsFeed - 12 Jun 2008
Teva Announces Tentative Approval of Generic Diovan(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 3 Dec 2007
FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Oct 2007
Ranbaxy Receives Tentative Approval For Valsartan Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 10 Aug 2007
FDA Grants Additional Six Months Marketing Exclusivity for the High Blood Pressure Medicine Diovan(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jun 2007
Exforge(R) Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Mar 2007
Tekturna(R), First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Dec 2006
Exforge(R) Receives US Regulatory Approval as a New and Highly Effective Treatment Option for Patients with High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 May 2006
Diovan(R) (valsartan) the First Blood Pressure Medication in a Large-Scale Clinical Trial to Lower C-Reactive Protein, an Important Marker of Inflammation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 17 May 2006
Novartis Announces Efficacy Data on New Investigational High Blood Pressure Therapies at The American Society of Hypertension Annual Meeting
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
valsartan
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.